Trials / Terminated
TerminatedNCT04332523
A Study of JNJ-53718678 in Participants With Hepatic Impairment
A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Pharmacokinetics of JNJ-53718678
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild, moderate, and severe) when compared with participants with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-53718678 | Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1. |
Timeline
- Start date
- 2020-08-17
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
- First posted
- 2020-04-02
- Last updated
- 2022-06-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04332523. Inclusion in this directory is not an endorsement.